An Act relative to pharmaceutical access, costs and transparency
- Introduced Dec 27, 2024
- In committee Dec 27, 2024
- Passed the Senate
- Passed the House Dec 30, 2024
- To the governor Dec 30, 2024
- Became law Jan 9, 2025
What it does
The legislature's own summary of the bill, or its official long title.
Senate, December 27, 2024 -- Report of the committee of conference on the disagreeing votes of the two branches with reference to the House amendment to the Senate relative to pharmaceutical access, costs and transparency (Senate, No. 2520) (amended by the House all after the enacting clause and inserting in place thereof the text of House document numbered 4910; and by striking out the title and inserting in place…
Read the full title (95 words)
Senate, December 27, 2024 -- Report of the committee of conference on the disagreeing votes of the two branches with reference to the House amendment to the Senate relative to pharmaceutical access, costs and transparency (Senate, No. 2520) (amended by the House all after the enacting clause and inserting in place thereof the text of House document numbered 4910; and by striking out the title and inserting in place thereof the following title: “An Act promoting access and affordability of prescription drugs.”),-- reports, a “Bill relative to pharmaceutical access, costs and transparency” (Senate, No. 3012).
Every action
13 steps, oldest first, as the legislature records them.
Show the 5 earlier steps
- SenateReported from a committee of conference
- SenateReported on S2520
- SenateRules suspended
- SenateCommittee of conference report accepted
- CommitteeReferred to the committee on House Steering, Policy and Scheduling · House Committee on Steering, Policy and Scheduling
- CommitteeCommittee reported that the matter be placed in the Orders of the Day for the next sitting, the question being on acceptance · House Committee on Steering, Policy and Scheduling
- HouseRules suspended
- HouseCommittee of conference report accepted, in concurrence
- HouseMotion to reconsider negatived
- HouseEnacted
- HouseMotion to reconsider negatived
- SenateEnacted and laid before the Governor
- GovernorSigned by the Governor, Chapter 342 of the Acts of 2024
Roll calls
No recorded votes on this bill yet.
Sponsors
The 0 members who introduced it, joined by 38 cosponsors: 28 Democrats, 9 Republicans, 1 Independent.
- Pa Pharmaceutical access, cost and transparency Sponsoring committee
All 38 cosponsors
- Angelo L. D'EmiliaR
- Bradley H. Jones, Jr.R
- Bruce E. TarrR
- Carmine Lawrence GentileD
- Carole A. FiolaD
- Christopher HendricksD
- Cindy F. FriedmanD
- Edward F. CoppingerD
- F. Jay BarrowsR
- Jack Patrick LewisD
- James B. EldridgeD
- Jason M. LewisD
- Joanne M. ComerfordD
- John J. Lawn, Jr.D
- Josh S. CutlerD
- Julian CyrD
- Kate HoganD
- Kimberly N. FergusonR
- Lindsay N. SabadosaD
- Marcus S. VaughnR
- Michael J. FinnD
- Michael O. MooreD
- Mindy DombD
- Natalie M. HigginsD
- Nicholas A. BoldygaR
- Patricia D. JehlenD
- Patrick M. O'ConnorR
- Paul R. FeeneyD
- Rebecca L. RauschD
- Rodney M. ElliottD
- Samantha MontañoD
- Smitty PignatelliD
- Steven OwensD
- Susan Williams GiffordR
- Susannah M. WhippsI
- Vanna HowardD
- William J. Driscoll, Jr.D
- William M. StrausD
From Massachusetts's official records (malegislature.gov/api), checked Nov 14, 2026. Text links go to the official versions; LegiList does not copy bill text.